HRP20150182T1 - Produžavanje preživljavanja transplantata inhibiranjem aktivnosti komplementa - Google Patents
Produžavanje preživljavanja transplantata inhibiranjem aktivnosti komplementa Download PDFInfo
- Publication number
- HRP20150182T1 HRP20150182T1 HRP20150182TT HRP20150182T HRP20150182T1 HR P20150182 T1 HRP20150182 T1 HR P20150182T1 HR P20150182T T HRP20150182T T HR P20150182TT HR P20150182 T HRP20150182 T HR P20150182T HR P20150182 T1 HRP20150182 T1 HR P20150182T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- use according
- immunosuppressive drug
- recipient mammal
- inhibitor
- Prior art date
Links
- 230000004083 survival effect Effects 0.000 title claims 3
- 230000024203 complement activation Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 241000124008 Mammalia Species 0.000 claims 19
- 239000003018 immunosuppressive agent Substances 0.000 claims 17
- 229940124589 immunosuppressive drug Drugs 0.000 claims 17
- 108010045851 interleukin 2 inhibitor Proteins 0.000 claims 12
- 238000009472 formulation Methods 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 11
- 229960002224 eculizumab Drugs 0.000 claims 7
- 206010029155 Nephropathy toxic Diseases 0.000 claims 6
- 230000007694 nephrotoxicity Effects 0.000 claims 6
- 231100000417 nephrotoxicity Toxicity 0.000 claims 6
- 229930105110 Cyclosporin A Natural products 0.000 claims 5
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical group CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 5
- 108010036949 Cyclosporine Proteins 0.000 claims 5
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 5
- 229950003203 pexelizumab Drugs 0.000 claims 5
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 5
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 5
- 229960002930 sirolimus Drugs 0.000 claims 5
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 5
- 229960001967 tacrolimus Drugs 0.000 claims 5
- 210000003734 kidney Anatomy 0.000 claims 4
- 229960001265 ciclosporin Drugs 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (46)
1. Anti-C5 antitijelo za uporabu u produžavanju preživljavanja bubrežnog transplantata u sisavcu primatelju, naznačeno time, što anti-C5 antitijelo inhibira siječenje C5 komponente komplementa na dijelove C5a i C5b i pri čemu se anti-C5 antitijelo primjenjuje kod sisavca primatelja zajedno sa inhibitorom IL-2 i imunosupresivnim lijekom koji nije udružen sa značajnom nefrotoksičnošću.
2. Anti-C5 antitijelo za uporabu prema zahtjevu 1, naznačeno time, što treba primijeniti više od jednog dodatnog imunosupresivnog lijeka.
3. Anti-C5 antitijelo za uporabu prema zahtjevu 1 ili 2, naznačeno time, što su spomenuto anti-C5 antitijelo, spomenuti inhibitor IL-2 i spomenuti imunosupresivni lijek u formulaciji ili formulacijama pogodnim za istovremenu primjenu kod spomenutog sisavca primatelja.
4. Anti-C5 antitijelo za uporabu prema bilo kojem od zahtjeva 1 do 3, naznačeno time, što su spomenuto anti-C5 antitijelo, spomenuti inhibitor IL-2 i spomenuti imunosupresivni lijek u formulaciji ili formulacijama pogodnim za sekvencijalnu primjenu kod spomenutog sisavca primatelja.
5. Anti-C5 antitijelo za uporabu prema bilo kojem od zahtjeva 1 do 4, naznačeno time, što je spomenuto anti-C5 antitijelo u formulaciji pogodnoj za stalnu primjenu kod spomenutog sisavca primatelja.
6. Anti-C5 antitijelo za uporabu prema bilo kojem od zahtjeva 1 do 5, naznačeno time, što je spomenuti inhibitor IL-2 ili spomenuti imunosupresivni lijek u formulaciji pogodnoj za stalnu primjenu kod spomenutog sisavca primatelja.
7. Anti-C5 antitijelo za uporabu prema bilo kojem od zahtjeva 1 do 6, naznačeno time, što spomenuti imunosupresivni lijek uključuje LF15-0195.
8. Anti-C5 antitijelo za uporabu prema bilo kojem od zahtjeva 1 do 7, naznačeno time, što je spomenuti sisavac primatelj čovjek.
9. Anti-C5 antitijelo za uporabu prema bilo kojem od zahtjeva 1 do 8, naznačeno time, što je spomenuti bubrežni transplantat MHC-nepodudaran.
10. Anti-C5 antitijelo za uporabu prema zahtjevu 9, naznačeno time, što je MHC-nepodudarni transplantat HLA-nepodudarni transplantat.
11. Anti-C5 antitijelo za uporabu prema bilo kojem od zahtjeva 1 do 8, naznačeno time, što je spomenuti sisavac primatelj ABO-nepodudaran sa spomenutim bubrežnim transplantatom.
12. Anti-C5 antitijelo za uporabu prema bilo kojem od zahtjeva 1 do 8, naznačeno time, što je spomenuti sisavac primatelj prethodno senzibiliziran na spomenuti bubrežni transplantat.
13. Anti-C5 antitijelo za uporabu prema bilo kojem od zahtjeva 1 do 12, naznačeno time, što je spomenuto anti-C5 antitijelo cijelo antitijelo ili dio antitijela.
14. Anti-C5 antitijelo za uporabu prema zahtjevu 13, naznačeno time, što je spomenuto cijelo antitijelo ili dio antitijela humano, humanizirano, himerizirano ili deimunizirano antitijelo ili dio antitijela.
15. Anti-C5 antitijelo za uporabu prema zahtjevu 13 ili 14, naznačeno time, što se spomenuti dio antitijela bira iz grupe koja se sastoji od Fab, F(ab')2, Fv, domenskog antitijela i jednolančanog antitijela.
16. Anti-C5 antitijelo za uporabu prema zahtjevu 13, naznačeno time, što je spomenuti dio antitijela pekselizumab.
17. Anti-C5 antitijelo za uporabu prema zahtjevu 13, naznačeno time, što je spomenuto cijelo antitijelo ekulizumab.
18. Anti-C5 antitijelo za uporabu prema zahtjevu 17, naznačeno time, što se spomenuti ekulizumab primjenjuje jednom svaka 2 tjedna.
19. Anti-C5 antitijelo za uporabu prema bilo kojem od zahtjeva 1 do 18, naznačeno time, što spomenuti bubrežni transplantat preživljava do kraja života spomenutog sisavca primatelja.
20. Anti-C5 antitijelo za uporabu prema bilo kojem od zahtjeva 1 do 18, naznačeno time, što spomenuti bubrežni transplantat preživljava najmanje tri mjeseca, najmanje šest mjeseci, najmanje 1 godinu ili najmanje pet godina.
21. Anti-C5 antitijelo za uporabu prema bilo kojem od zahtjeva 1 do 20, naznačeno time, što se spomenuto anti-C5 antitijelo primjenjuje stalno tokom najmanje 14 dana, najmanje 28 dana, najmanje 3 mjeseca, najmanje 6 mjeseci, najmanje 1 godinu, ili najmanje 5 godina.
22. Anti-C5 antitijelo za uporabu prema bilo kojem od zahtjeva 1 do 21, naznačeno time, što se spomenuto anti-C5 antitijelo primjenjuje stalno do kraja života spomenutog sisavca primatelja.
23. Anti-C5 antitijelo za uporabu prema bilo kojem od zahtjeva 1 do 22, naznačeno time, što se spomenuti imunosupresivni lijek primjenjuje stalno do kraja života spomenutog sisavca primatelja.
24. Anti-C5 antitijelo za uporabu prema bilo kojem od zahtjeva 1 do 13, naznačeno time, što je spomenuto anti-C5 antitijelo ekulizumab ili pekselizumab; pri čemu se spomenuti inhibitor IL-2 bira iz grupe koja se sastoji od ciklosporina A, takrolimusa i sirolimusa; i pri čemu je spomenuti imunosupresivni lijek LF15- 0195.
25. Anti-C5 antitijelo za uporabu prema bilo kojem od zahtjeva 1 do 23, naznačeno time, što je spomenuti inhibitor IL-2 ciklosporin A, takrolimus ili sirolimus.
26. Uporaba anti-C5 antitijela, inhibitora IL-2 i imunosupresivnog lijeka u izradi medikamenta ili pakovanja medikamenta za produženje preživljavanja bubrežnog transplantata u sisavcu primatelju, naznačena time, što spomenuti imunosupresivni lijek nije udružen sa značajnom nefrotoksičnošću i pri čemu anti-C5 antitijelo inhibira sječenje C5 komponente komplementa na dijelove C5a i C5b.
27. Uporaba prema zahtjevu 26, naznačena time, što je spomenuti sisavac čovjek.
28. Uporaba prema zahtjevu 26 ili 27, naznačena time, što se koristi više od jednog imunosupresivnog lijeka.
29. Uporaba prema bilo kojem od zahtjeva 26 do 28, naznačena time, što su spomenuto anti-C5 antitijelo, spomenuti inhibitor IL-2 i spomenuti imunosupresivni lijek koji nije udružen sa značajnom nefrotoksičnošću u formulaciji pogodnoj za istovremenu primjenu kod spomenutog sisavca primatelja ili pri čemu su spomenuto anti-C5 antitijelo, spomenuti inhibitor IL-2 i spomenuti imunosupresivni lijek koji nije udružen sa značajnom nefrotoksičnošću u formulaciji ili formulacijama pogodnim za sekvencijalnu primjenu kod spomenutog sisavca primatelja.
30. Uporaba prema bilo kojem od zahtjeva 26 do 29, naznačena time, što je spomenuto anti-C5 antitijelo u formulaciji pogodnoj za stalnu primjenu kod spomenutog sisavca primatelja.
31. Uporaba prema bilo kojem od zahtjeva 26 do 30, naznačena time, što je spomenuti imunosupresivni lijek koji nije udružen sa značajnom nefrotoksičnošću u formulaciji pogodnoj za stalnu primjenu kod spomenutog sisavca primatelja.
32. Uporaba prema bilo kojem od zahtjeva 26 do 31, naznačena time, što spomenuti imunosupresivni lijek koji nije udružen sa značajnom nefrotoksičnošću uključuje LF15-0195.
33. Uporaba prema bilo kojem od zahtjeva 26 do 32, naznačena time, što je spomenuti inhibitor IL-2 ciklosporin A, takrolimus ili sirolimus.
34. Uporaba anti-C5 antitijela prema bilo kojem od zahtjeva 26 do 33, naznačena time, što je spomenuto anti-C5 antitijelo cijelo antitijelo ili dio antitijela.
35. Uporaba prema zahtjevu 34, naznačena time, što je spomenuto cijelo antitijelo ili dio antitijela humano, humanizirano, himerizirano ili deimunizirano antitijelo ili dio antitijela.
36. Uporaba prema zahtjevu 34 ili 35, naznačena time, što se spomenuti dio antitijela bira iz grupe koja se sastoji od Fab, F(ab')2, Fv, domenskog antitijela i jednolančanog antitijela.
37. Uporaba prema zahtjevu 34, naznačena time, što je spomenuti dio antitijela pekselizumab ili je spomenuto cijelo antitijelo ekulizumab.
38. Uporaba prema zahtjevu 37, naznačena time, što se ekulizumab primjenjuje jednom svaka 2 tjedna.
39. Uporaba prema bilo kojem od zahtjeva 26 do 38, naznačena time, što spomenuti bubrežni transplantat preživljava do kraja života spomenutog sisavca primatelja.
40. Uporaba prema bilo kojem od zahtjeva 26 do 38, naznačena time, što spomenuti bubrežni transplantat preživljava najmanje tri mjeseca, najmanje šest mjeseci, najmanje 1 godinu ili najmanje pet godina.
41. Uporaba prema bilo kojem od zahtjeva 26 do 40, naznačena time, što se spomenuto anti-C5 antitijelo primjenjuje stalno tokom najmanje 14 dana, najmanje 28 dana, najmanje 3 mjeseca, najmanje 6 mjeseci, najmanje 1 godine, ili najmanje 5 godina.
42. Uporaba prema bilo kojem od zahtjeva 26 do 40, naznačena time, što se spomenuto anti-C5 antitijelo primjenjuje stalno do kraja života spomenutog sisavca primatelja.
43. Uporaba prema bilo kojem od zahtjeva 26 do 42, naznačena time, što se spomenuti imunosupresivni lijek primjenjuje stalno do kraja života spomenutog sisavca primatelja.
44. Uporaba prema bilo kojem od zahtjeva 26 do 33, naznačena time, što je spomenuto anti-C5 antitijelo ekulizumab ili pekselizumab; pri čemu se spomenuti inhibitor IL-2 bira iz grupe koja se sastoji od ciklosporina A, takrolimusa i sirolimusa; i pri čemu je spomenuti imunosupresivni lijek LF15-0195.
45. Farmaceutsko pakiranje, naznačeno time, što sadrži: (a) anti-C5 antitijelo; (b) inhibitor IL-2 i (c) LF15-0195, pri čemu su spomenuto anti-C5 antitijelo i spomenuti LF15-0195 formulirani za stalnu primjenu.
46. Farmaceutsko pakiranje prema zahtjevu 45, naznačeno time, što je spomenuto anti-C5 antitijelo ekulizumab ili pekselizumab i pri čemu se spomenuti inhibitor IL-2 bira iz grupe koja se sastoji od ciklosporina A, takrolimusa i sirolimusa.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77885906P | 2006-03-02 | 2006-03-02 | |
| PCT/US2007/005290 WO2007103134A2 (en) | 2006-03-02 | 2007-03-02 | Prolongation of survival of an allograft by inhibiting complement activity |
| EP07752018.7A EP1988882B1 (en) | 2006-03-02 | 2007-03-02 | Prolongation of survival of an allograft by inhibiting complement activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150182T1 true HRP20150182T1 (hr) | 2015-06-05 |
Family
ID=38475394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150182TT HRP20150182T1 (hr) | 2006-03-02 | 2015-02-16 | Produžavanje preživljavanja transplantata inhibiranjem aktivnosti komplementa |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20100135992A1 (hr) |
| EP (2) | EP1988882B1 (hr) |
| JP (2) | JP5722524B2 (hr) |
| KR (2) | KR101527225B1 (hr) |
| CN (1) | CN101437501B (hr) |
| AU (1) | AU2007224250B2 (hr) |
| BR (1) | BRPI0708424A2 (hr) |
| CA (1) | CA2644020C (hr) |
| DK (1) | DK1988882T3 (hr) |
| ES (1) | ES2530637T3 (hr) |
| HK (1) | HK1120444A1 (hr) |
| HR (1) | HRP20150182T1 (hr) |
| IL (1) | IL193623A0 (hr) |
| MX (1) | MX2008011054A (hr) |
| NZ (1) | NZ570802A (hr) |
| PL (1) | PL1988882T3 (hr) |
| PT (1) | PT1988882E (hr) |
| RS (1) | RS53864B1 (hr) |
| RU (1) | RU2445975C2 (hr) |
| SG (1) | SG171578A1 (hr) |
| SI (1) | SI1988882T1 (hr) |
| WO (1) | WO2007103134A2 (hr) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090220508A1 (en) | 2006-03-15 | 2009-09-03 | Alexion Pharmaceuticals, Inc. | Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement |
| JP5624276B2 (ja) | 2006-03-31 | 2014-11-12 | 中外製薬株式会社 | 抗体の血中動態を制御する方法 |
| EP2913342A1 (en) * | 2006-09-05 | 2015-09-02 | Alexion Pharmaceuticals, Inc. | Compositions for use in the treatment of antibody mediated neuropathies |
| JP2010505946A (ja) | 2006-10-10 | 2010-02-25 | アカデミシュ ジーケンハウス ビイ デ ユニヴェアズィテート ファン アムステルダム | 神経再生改善のための補体阻害 |
| EP3689912A1 (en) | 2007-09-26 | 2020-08-05 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
| TWI564021B (zh) | 2008-04-11 | 2017-01-01 | Chugai Pharmaceutical Co Ltd | Repeated binding of antigen to antigen binding molecules |
| ES2940466T3 (es) * | 2008-11-10 | 2023-05-08 | Alexion Pharma Inc | Métodos y composiciones para tratar trastornos asociados al complemento |
| US20130028897A1 (en) * | 2009-04-27 | 2013-01-31 | Ali Naji | Methods for reducing the level of alloantibodies in a subject |
| AU2010264520A1 (en) * | 2009-06-23 | 2012-01-19 | Alexion Pharmaceuticals, Inc. | Bispecific antibodies that bind to complement proteins |
| ME01699B (me) * | 2009-07-02 | 2014-09-20 | Musc Found For Res Dev | Metode za stimulaciju regeneracije jetre |
| CN101621801B (zh) * | 2009-08-11 | 2012-11-28 | 华为终端有限公司 | 无线局域网的认证方法、***及服务器、终端 |
| MX365235B (es) | 2010-11-30 | 2019-05-28 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno. |
| AU2012256281B2 (en) * | 2011-05-16 | 2017-06-15 | Genzyme Corporation | Induction of immune tolerance by using methotrexate |
| CN102585016B (zh) * | 2012-03-06 | 2014-06-04 | 江苏健德生物药业有限公司 | 一种可同时抑制t、b淋巴细胞功能的免疫融合蛋白、其制备方法及其应用 |
| CN103232542B (zh) * | 2013-02-01 | 2015-05-13 | 殷勇 | 一种双靶标嵌合蛋白 |
| EA034870B1 (ru) | 2013-08-07 | 2020-03-31 | Алексион Фармасьютикалз, Инк. | Белковые биомаркеры атипичного гемолитического уремического синдрома |
| WO2015023972A1 (en) * | 2013-08-16 | 2015-02-19 | Alexion Pharmaceuticals, Inc. | Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant |
| NZ719724A (en) * | 2013-11-22 | 2022-08-26 | Takeda Pharmaceuticals Co | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor |
| NZ711451A (en) | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| CN113045650A (zh) | 2014-12-19 | 2021-06-29 | 中外制药株式会社 | 抗-c5抗体及使用方法 |
| WO2017075325A1 (en) * | 2015-10-30 | 2017-05-04 | Alexion Pharmaceuticals, Inc. | A method of inhibiting exacerbations of t cell-mediated allograft vasculopathy |
| CR20180364A (es) * | 2015-12-18 | 2018-08-22 | Chugai Pharmaceutical Co Ltd | Anticuerpos anti-c5 y métodos de uso |
| CN109310759A (zh) * | 2016-06-07 | 2019-02-05 | 诺华股份有限公司 | 用于在移植排斥治疗中使用的特斯多鲁单抗 |
| WO2017212391A1 (en) * | 2016-06-07 | 2017-12-14 | Novartis Ag | An anti-c5 antibody dosing regimen |
| JP7102353B2 (ja) | 2016-06-14 | 2022-07-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｃ５抗体及びそれらの使用 |
| CA3026050A1 (en) | 2016-08-05 | 2018-02-08 | Chugai Seiyaku Kabushiki Kaisha | Composition for prophylaxis or treatment of il-8 related diseases |
| DK3658184T3 (da) | 2017-07-27 | 2023-11-27 | Alexion Pharma Inc | Højkoncentrerede anti-c5-antistofformuleringer |
| MA51147A (fr) | 2017-12-13 | 2021-03-24 | Regeneron Pharma | Associations d'anticorps anti-c5 et utilisations associées |
| CN111449050A (zh) * | 2019-01-20 | 2020-07-28 | 睿诺医疗科技（上海）有限公司 | 环孢菌素类似物及其用途 |
| US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| WO2021146471A2 (en) * | 2020-01-15 | 2021-07-22 | The Regents Of The University Of California | Transplanted cell protection via inhibition of polymorphonuclear cells |
| CN114532982A (zh) * | 2022-01-12 | 2022-05-27 | 高谋 | 评价干细胞***移植调控补体活化作用的体系 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2588579B2 (ja) | 1988-04-21 | 1997-03-05 | 株式会社クラレ | 耐熱水性にすぐれたポリビニルアルコール系繊維およびその製造法 |
| US5573940A (en) * | 1989-06-12 | 1996-11-12 | Oklahoma Medical Research Foundation | Cells expressing high levels of CD59 |
| US5135916A (en) * | 1989-06-12 | 1992-08-04 | Oklahoma Medical Research Foundation | Inhibition of complement mediated inflammatory response |
| US5705732A (en) | 1989-06-12 | 1998-01-06 | Oklahoma Medical Research Foundation | Universal donor cells |
| US20010018051A1 (en) * | 1990-04-09 | 2001-08-30 | White David James Graham | Inhibition of allograft and concordant xenograft rejection |
| WO1992010205A1 (en) * | 1990-12-06 | 1992-06-25 | T Cell Sciences, Inc. | Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity |
| US5456909A (en) * | 1992-08-07 | 1995-10-10 | T Cell Sciences, Inc. | Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo |
| US5308341A (en) | 1993-09-28 | 1994-05-03 | Becton, Dickinson And Company | Method of testing the dose accuracy of a medication delivery device |
| US5683693A (en) * | 1994-04-25 | 1997-11-04 | Trustees Of Dartmouth College | Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40 |
| US6074642A (en) * | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US5679345A (en) * | 1994-06-02 | 1997-10-21 | The Johns Hopkins University | Method for preventing complement-dependent rejection of organ or tissue transplants |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US5962019A (en) * | 1995-08-25 | 1999-10-05 | Sangstat Medical Corporation | Oral cyclosporin formulations |
| US6355242B1 (en) * | 1997-05-23 | 2002-03-12 | Ixion Biotechnology, Inc. | Materials and methods for treating or preventing oxalate-related disease |
| AU746825B2 (en) * | 1998-02-04 | 2002-05-02 | Brigham And Women's Hospital | Costimulatory blockade and mixed chimerism in allotransplantation |
| US6302855B1 (en) | 1998-05-20 | 2001-10-16 | Novo Nordisk A/S | Medical apparatus for use by a patient for medical self treatment of diabetes |
| AU1521000A (en) | 1998-11-06 | 2000-05-29 | Schepens Eye Research Institute, Inc., The | Local use of soluble tumor necrosis receptor i (stnfri) for prophylaxis and treatment of corneal transplant rejection and other disorders of the eye |
| US6192891B1 (en) * | 1999-04-26 | 2001-02-27 | Becton Dickinson And Company | Integrated system including medication delivery pen, blood monitoring device, and lancer |
| AUPQ431299A0 (en) | 1999-11-26 | 1999-12-23 | Unisearch Limited | Method of inducing immune tolerance |
| US6538028B1 (en) * | 2000-02-01 | 2003-03-25 | Vanderbilt University | Method for inhibiting complement activation |
| PT1325033E (pt) | 2000-10-10 | 2010-04-15 | Genentech Inc | Inibição da activação do complemento c5 para o tratamento e a prevenção da rejeição diferida de um xenoenxertos ou de uma rejeição vascular aguda |
| ATE424893T1 (de) * | 2001-06-08 | 2009-03-15 | Novartis Pharma Gmbh | Behandlung und vorbeugung von insulin- produzierende zelltransplantatabstossung |
| ES2283594T5 (es) * | 2001-08-17 | 2016-03-15 | Genentech, Inc. | Inhibidores de la ruta del complemento que se unen a C5 y C5a sin impedir la formación de C5b |
| JP4564261B2 (ja) * | 2002-01-22 | 2010-10-20 | ジェンザイム、コーポレーション | 慢性的移植片拒絶反応の治療と予防のためのＴＧＦ−β拮抗薬の使用 |
| US20040146503A1 (en) * | 2002-08-28 | 2004-07-29 | Tesi Raymond J. | Methods and compositions for inducing stable immune tolerance |
| US7923010B2 (en) * | 2003-09-11 | 2011-04-12 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune diseases and conditions |
| US20050169921A1 (en) * | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| SI1755674T1 (sl) * | 2004-05-14 | 2015-04-30 | Alexion Pharmaceuticals, Inc. | Podaljšanje preživetja alotransplantata z inhibiranjem aktivnosti komplementa |
| CN1980649A (zh) * | 2004-05-17 | 2007-06-13 | 康宾纳特克斯公司 | 治疗免疫炎性疾病的方法和试药 |
-
2007
- 2007-03-02 SI SI200731610T patent/SI1988882T1/sl unknown
- 2007-03-02 KR KR1020087023398A patent/KR101527225B1/ko not_active IP Right Cessation
- 2007-03-02 MX MX2008011054A patent/MX2008011054A/es active IP Right Grant
- 2007-03-02 AU AU2007224250A patent/AU2007224250B2/en active Active
- 2007-03-02 RS RS20150109A patent/RS53864B1/en unknown
- 2007-03-02 DK DK07752018.7T patent/DK1988882T3/en active
- 2007-03-02 KR KR1020147028450A patent/KR101650264B1/ko active IP Right Grant
- 2007-03-02 US US12/224,567 patent/US20100135992A1/en not_active Abandoned
- 2007-03-02 CA CA2644020A patent/CA2644020C/en not_active Expired - Fee Related
- 2007-03-02 NZ NZ570802A patent/NZ570802A/en not_active IP Right Cessation
- 2007-03-02 WO PCT/US2007/005290 patent/WO2007103134A2/en active Application Filing
- 2007-03-02 JP JP2008557383A patent/JP5722524B2/ja not_active Expired - Fee Related
- 2007-03-02 ES ES07752018T patent/ES2530637T3/es active Active
- 2007-03-02 BR BRPI0708424-2A patent/BRPI0708424A2/pt not_active IP Right Cessation
- 2007-03-02 CN CN200780015830XA patent/CN101437501B/zh active Active
- 2007-03-02 SG SG201102357-9A patent/SG171578A1/en unknown
- 2007-03-02 EP EP07752018.7A patent/EP1988882B1/en not_active Revoked
- 2007-03-02 RU RU2008139118/15A patent/RU2445975C2/ru not_active IP Right Cessation
- 2007-03-02 PL PL07752018T patent/PL1988882T3/pl unknown
- 2007-03-02 PT PT77520187T patent/PT1988882E/pt unknown
- 2007-03-02 EP EP14198274.4A patent/EP2918269A1/en not_active Withdrawn
-
2008
- 2008-08-21 IL IL193623A patent/IL193623A0/en unknown
-
2009
- 2009-02-11 HK HK09101244.3A patent/HK1120444A1/xx not_active IP Right Cessation
-
2013
- 2013-05-20 JP JP2013105946A patent/JP2013155202A/ja not_active Withdrawn
-
2015
- 2015-02-16 HR HRP20150182TT patent/HRP20150182T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ570802A (en) | 2012-03-30 |
| AU2007224250B2 (en) | 2012-05-03 |
| SG171578A1 (en) | 2011-06-29 |
| CA2644020A1 (en) | 2007-09-13 |
| KR101527225B1 (ko) | 2015-06-08 |
| IL193623A0 (en) | 2009-08-03 |
| EP1988882B1 (en) | 2014-12-17 |
| JP5722524B2 (ja) | 2015-05-20 |
| EP1988882A2 (en) | 2008-11-12 |
| PL1988882T3 (pl) | 2015-04-30 |
| ES2530637T3 (es) | 2015-03-04 |
| MX2008011054A (es) | 2009-03-03 |
| JP2013155202A (ja) | 2013-08-15 |
| PT1988882E (pt) | 2015-02-17 |
| WO2007103134A3 (en) | 2008-09-12 |
| EP2918269A1 (en) | 2015-09-16 |
| SI1988882T1 (sl) | 2015-07-31 |
| HK1120444A1 (en) | 2009-04-03 |
| RU2008139118A (ru) | 2010-04-10 |
| KR20080098543A (ko) | 2008-11-10 |
| WO2007103134A2 (en) | 2007-09-13 |
| CN101437501B (zh) | 2012-09-05 |
| BRPI0708424A2 (pt) | 2011-05-31 |
| DK1988882T3 (en) | 2015-02-23 |
| JP2009528369A (ja) | 2009-08-06 |
| KR101650264B1 (ko) | 2016-08-22 |
| RS53864B1 (en) | 2015-08-31 |
| US20100135992A1 (en) | 2010-06-03 |
| CA2644020C (en) | 2016-05-10 |
| AU2007224250A1 (en) | 2007-09-13 |
| CN101437501A (zh) | 2009-05-20 |
| KR20140124023A (ko) | 2014-10-23 |
| RU2445975C2 (ru) | 2012-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150182T1 (hr) | Produžavanje preživljavanja transplantata inhibiranjem aktivnosti komplementa | |
| Smith et al. | Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use | |
| Liu et al. | Basiliximab or antithymocyte globulin for induction therapy in kidney transplantation: a meta-analysis | |
| Pengel et al. | Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials | |
| Falagas et al. | Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence | |
| Rostaing et al. | Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study | |
| JP2009528369A5 (hr) | ||
| TW200640487A (en) | Combination of XOLAIR with immunosuppressive agent | |
| JP2010534243A5 (hr) | ||
| JP2015172090A5 (hr) | ||
| JP2019517505A5 (hr) | ||
| CL2007003855A1 (es) | Composicion que comprende un vehiculo sustrato y un deposito sobre dicho vehiculo sustrato, donde dicho deposito comprende particulas de un compuesto derivado de pregnano; capsula y tableta que la comprenden; y uso en el tratamiento de enfermedades t | |
| CL2008002380A1 (es) | Composicion farmaceutica de liberacion prolongada que comprende micofenolato sodico, al menos un material de control de liberacion y opcionalmente excipientes; y su uso en el tratamiento de enfermedades que requieren de inmunosupresores, tales como trasplantes, injertos o enfermedades autoinmunes. | |
| Sadaka et al. | Proteasome inhibition for antibody-mediated allograft rejection | |
| PE20091714A1 (es) | Combinacion del inhibidor hgf y el agonista pten | |
| Tasaki et al. | Bortezomib eliminates plasma cells from a renal graft in plasma cell–rich acute rejection | |
| Stevens et al. | A randomized 2× 2 factorial trial, part 1: single-dose rabbit antithymocyte globulin induction may improve renal transplantation outcomes | |
| Matia et al. | The positive effect of immunosuppression on adaptation of venous allografts to arterialisation in rats | |
| Eggleston | Cockroach allergy and urban asthma | |
| Santos et al. | Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience | |
| Dupuis et al. | Experience with low-dose valganciclovir prophylaxis in adult liver transplant recipients | |
| Gruttadauria et al. | A safe immunosuppressive protocol in adult-to-adult living related liver transplantation | |
| Poirier et al. | Recombinant human C1-inhibitor inhibits cytotoxicity induced by allo-and xenoantibodies | |
| Tilney | Renal transplantation | |
| Wszola et al. | Long term medical and economical benefit of machine perfusion (MP) kidney storage in comparison to cold storage (CS) |